Pharmacokinetics, biodistribution and targeting of 111 in- labeled humanized PAM4IgG [monoclonal antibody PAM4] in pre-surgical pancreatic cancer patients.An examination of protein dose

Trial Profile

Pharmacokinetics, biodistribution and targeting of 111 in- labeled humanized PAM4IgG [monoclonal antibody PAM4] in pre-surgical pancreatic cancer patients.An examination of protein dose

Discontinued
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2008

At a glance

  • Drugs Monoclonal antibody PAM4 (Primary)
  • Indications Pancreatic cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Dec 2008 Status changed from recruiting to discontinued.
    • 09 Oct 2007 The expected completion date for this trial is now 1 Jun 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top